BA
TAK icon

BKS Advisors’s Takeda Pharmaceutical TAK Stock Holding History

BKS Advisors’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$428K Buy
+20,993
New +$422K 0.17% 124

Other funds holding TAK

GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
AC
Adelphi Capital London, United Kingdom $3.21M AUM 121.6% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
SHCM
Sachem Head Capital Management New York $4.15B AUM 48.05% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

BKS Advisors's TAK Position: Q1 2019 in Review

BKS Advisors opened a new position in Takeda Pharmaceutical (TAK) in Q1 2019: 20,993 shares worth $428K. The stake represents 0.17% of the portfolio and ranks #124 among its holdings.

390 funds tracked by Wall St. Rank hold TAK as of Q1 2019.

  • BKS Advisors held 20,993 shares of Takeda Pharmaceutical worth $428K as of Q1 2019.
  • Takeda Pharmaceutical was a new BKS Advisors position in Q1 2019.
  • Takeda Pharmaceutical made up 0.17% of BKS Advisors's portfolio in Q1 2019, its #124 holding.
  • 390 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q1 2019.

Based on BKS Advisors's 13F filing for Q1 2019, filed 16 Apr 2019.